GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today revealed final data from its Vivity® Registry Study, which monitored real-world patient experiences for up to 12 months post cataract surgery with implantation of either AcrySof® IQ Vivity® or AcrySof® IQ Vivity® Toric presbyopia-correcting intraocular lens (PCIOL).

日内瓦-（商业线）-Alcon（SIX/NYSE:ALC）是全球眼保健领导者，致力于帮助人们出色地看待，今天揭示了其Vivity®注册研究的最终数据，通过植入AcrySof®IQVivity®或AcrySof®IQVivity®Toric老花眼矫正人工晶状体（PCIOL），监测白内障手术后长达12个月的真实患者体验。

Data from more than 900 cataract patients demonstrated sustained clinical performance, high patient satisfaction and reduced dependence upon spectacles (glasses). Evidence also suggested that AcrySof® IQ Vivity® can be used successfully in a broad range of patients, providing surgeons and patients with additional treatment options..

来自900多名白内障患者的数据显示出持续的临床表现，较高的患者满意度以及对眼镜（眼镜）的依赖性降低。有证据表明，AcrySof®IQVivity®可成功用于广泛的患者，为外科医生和患者提供额外的治疗选择。。

“Since its introduction, AcrySof® IQ Vivity® has been a disruptive technology—and an innovation we are very proud of as a company. Vivity® is a first-of-its kind, non-diffractive extended depth of focus IOL built with our proprietary X-WAVETM technology, which stretches and shifts light without splitting it,” said Sunil Vasanth, VP, Europe Surgical Franchise, Alcon.

“自推出以来，AcrySof®iQvivity®一直是一项颠覆性技术和创新，我们为公司感到非常自豪.Vivity®是我们专有的第一款无衍射扩展深度IOL X-WAVETM技术，可以伸展和移动光线而不分裂它，”Sunil Vasanth，副总裁，欧洲外科特许经营，Alcon表示。

“Our real-world registry data gives surgeons the confidence that Vivity’s performance is sustained over time. This data is also important as it includes patients with common mild comorbidities like glaucoma, dry eye and retinopathy/maculopathy.”.

“我们的现实世界的注册数据使外科医生相信Vivity的表现会持续一段时间，这些数据也很重要，因为它包括常见轻度合并症患者，如青光眼，干眼症和视网膜病变/黄斑病变。”。

The Vivity® Registry Study3 was a multicentre, ambispective, non-comparative, open-label, non-interventional registry study conducted across 41 sites from eight (8) countries: Australia, Belgium, Germany, New Zealand, the Netherlands, Portugal, Spain and the United Kingdom. Researchers concluded that:3.

Vivity®注册研究3是来自八（8）个国家（澳大利亚，比利时，德国，新西兰，荷兰，葡萄牙，西班牙和英国。研究人员得出结论：3。

Three-quarters of patients reported no difficulty with their sight for activities in everyday life∞

四分之三的患者报告说他们在日常生活中的活动没有视力障碍∞

Most patients (92%) reported they were satisfied with their sight‡

大多数患者（92%）报告他们对自己的视力感到满意‡

More than 91% of patients reported no halos, glares or starbursts† (common visual disturbances that come from splitting the light in a diffractive IOL)

超过91%的患者报告没有光晕，眩光或星爆†（常见的视觉障碍来自衍射IOL中的光线分裂）

Excellent binocular distance and intermediate uncorrected visual acuity was observed, with mean Snellen visual acuity values of 20/20 and 20/25, respectively

观察到良好的双眼距离和中等程度的未矫正视力，平均Snellen视力值分别为20/20和20/25

More than 78% and 88% of patients reported they no longer needed to use glasses to see at arm’s length and far away, respectively§

超过78%和88%的患者报告他们不再需要使用眼镜来观察手臂的长度和远处

These results and additional data are being discussed in 11 sessions with world-renowned surgeons at the 41st Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), currently underway in Vienna, Austria. For a full overview of relevant abstracts, please visit MyAlconatESCRS.com..

这些结果和其他数据正在与欧洲白内障和屈光外科医师协会（ESCRS）第41届大会上的世界知名外科医生进行11次会议讨论，目前正在奥地利维也纳进行。有关相关摘要的完整概述，请访问MyAlconatESCRS.com。。

AcrySof® IQ Vivity®, a non-diffractive IOL, uses Alcon’s proprietary Wavefront-Shaping X-WAVETM technology, a next-generation optical principle that stretches and shifts light without splitting it.2 As a result, it fulfils an unmet medical need to provide excellent distance, intermediate and functional near vision (e.g., for close-up daily activities such as using a mobile device), while maintaining low visual disturbances.2.

AcrySof®iQvivity®是一种非衍射IOL，采用Alcon专有的波前整形X-WAVETM技术，这是一种新一代光学原理，可在不分裂的情况下拉伸和移动光线.2因此，它满足了未满足的医疗需求，可提供出色的距离，中间和功能性近视（例如，用于特写日常活动，例如使用移动设备），同时保持较低的视觉障碍。

Vision is at the top of people’s minds as they get older—and surgeons can make a difference

随着年龄的增长，视力成为人们的最佳选择，外科医生可以有所作为

According to a new Global Alcon Survey, vision ties with mobility as the second most important quality of ageing (83%), with only memory scoring higher at 84%.4,* For people already diagnosed with cataracts, vision is the most important concern when it comes to ageing. According to the survey, cataract patients report they have an improvement in quality of life post-surgery, including 81% of patients who received any PCIOL.

根据一项新的全球爱尔康调查，视力与流动性成为第二重要的衰老质量（83%），只有记忆力得分高于84%.4，*对于已经诊断患有白内障的人，视力是最重要的涉及衰老时的关注。根据调查，白内障患者报告他们的手术后生活质量有所改善，其中81%的患者接受了任何PCIOL。

Additionally, 69% of all people surveyed, including those who have not been diagnosed with cataracts, would feel liberated without their glasses. Of those diagnosed with cataracts and awaiting surgery, 3 in 4 reported that they would be willing to pay for a lens that eliminates the need for spectacles.4.

此外，所有接受调查的人中有69%，包括那些没有被诊断患有白内障的人，如果没有眼镜就会感到解放。在那些被诊断患有白内障并等待手术的人中，有四分之三的人报告说他们愿意为不需要眼镜的镜片付费。

Vision plays a powerful role in empowering people as they age. AcrySof® IQ Vivity® can help to meet patient demands and expectations related to performance, quality of life and spectacle independence.

视力在赋予人们年龄增长的能力方面发挥着强大的作用。AcrySof®IQVivity®可以帮助满足患者对性能，生活质量和眼镜独立性的需求和期望。

AcrySof® IQ Vivity® and AcrySof® IQ Vivity® Toric may not be approved in all markets; please reach out to your Alcon Rep for questions about availability in your local market. Please refer to relevant products DFU or Operator’s manuals for complete list of indications, contraindications and warnings..

AcrySof®IQVivity®和AcrySof®IQVivity®Toric可能无法在所有市场上获得批准；请联系您的Alcon代表，了解有关当地市场可用性的问题。有关适应症，禁忌症和警告的完整列表，请参阅相关产品DFU或操作员手册。。

This content is intended for Healthcare Professionals (HCPs) only. Please note that product related promotion of Medical Devices to non-HCPs may be subject to restrictions based on local rules and regulations.

本内容仅适用于医疗保健专业人员（HCP）。请注意，与非HCP相关的医疗器械产品促销可能会受到当地法规的限制。

About the AcrySof® IQ Vivity® IOL

关于AcrySof®IQVivity®IOL

The non-diffractive AcrySof® IQ Vivity® Extended Vision Posterior Chamber Intraocular Lens Model DFT015 (referred to as AcrySof® IQ Vivity® IOL) is a UV-absorbing and blue light filtering foldable intraocular lens (IOL). This IOL, compared to a monofocal IOL, provides an extended range of vision from distance to near without increasing the incidence of visual disturbances..

无衍射AcrySof®IQVivity®Extended Vision后房型人工晶状体DFT015（称为AcrySof®IQVivity®IOL）是一种紫外线吸收和蓝光过滤可折叠人工晶状体（IOL）。与单焦点IOL相比，该IOL可提供从远处到近距离的扩展视觉范围，而不会增加视觉障碍的发生率。。

Potential side effects: As with any surgery, there is an implicit risk, whether or not the IOL is implanted. The complications of the IOL implantation surgery ranges from minor side effects (usually temporary) to serious complications. Patients with previous illnesses or disorders (such as chronic infections of the eye or eyelids, or diabetes) may present a higher risk of complications.

潜在的副作用：与任何手术一样，无论IOL是否植入，都存在隐含的风险。IOL植入手术的并发症范围从轻微的副作用（通常是暂时的）到严重的并发症。患有先前疾病或病症（例如眼睛或眼睑的慢性感染，或糖尿病）的患者可能具有较高的并发症风险。

Temporary surgical complications include, but are not limited to, reactions to medications such as irritation or mild allergic response, bleeding, redness, itching of the eye, sensitivity to light, swelling, corneal edema (swelling of the cornea), problems with the iris, cell growth in the IOL, and an increase temporary eye pressure.

临时手术并发症包括但不限于对药物的反应，例如刺激或轻度过敏反应，出血，发红，眼睛瘙痒，对光敏感，肿胀，角膜水肿（角膜肿胀），虹膜问题，IOL中的细胞生长，以及增加临时眼压。

There is a small risk of needing further surgical treatment (such as IOL replacement implanted by a different one or surgery to improve vision) after the implantation of the initial IOL..

在植入初始IOL之后，需要进一步手术治疗（例如通过不同的手术植入IOL或手术以改善视力）的风险很小。。

About Alcon

关于爱尔康

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors.

爱尔康帮助人们出色地看到。作为具有75年历史的全球眼保健领导者，我们提供最广泛的产品组合，以增强视力并改善人们的生活。我们的手术和视力护理产品每年接触140多个国家超过2.6亿人的生活，这些人患有白内障，青光眼，视网膜疾病和屈光不正等疾病。

Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com..

我们的25000多名员工正在通过创新产品，与眼保健专业人员的合作伙伴关系以及促进获得优质眼保健的计划来提高生活质量。在www.alcon.com了解更多信息。。

References

工具书类

AcrySof® IQ Vivity® Extended Vision IOL DFU.

AcrySof®IQVivity®扩展视觉IOL DFU。

Bala et al. Multicountry clinical outcomes of a new nondiffractive presbyopia-correcting IOL. J Cataract Refract Surg 2022; 48:136–143.

Bala等。一种新的非差异性老花眼矫正IOL的多国临床结果。J Cataract Refract Surg 2022；48:136–143.

Reus NJ, Kooijman M, Perez-Vives C. Overall Visual Outcomes from a Real-world Study of Presbyopia-correcting IOLs in a Large Population. Presented at the European Society of Cataract and Refractive Surgery (ESCRS) Annual Meeting; 8-12 Sept, 2023; Vienna, Austria.

Reus NJ，Kooijman M，Perez-Vives C.在大量人群中对老花眼矫正人工晶状体的现实世界研究的总体视觉结果。在欧洲白内障和屈光手术学会（ESCRS）年会上发表；2023年9月8日至12日；维也纳，奥地利。

Alcon Cataract Survey [REF-21516].

爱尔康白内障调查[REF-21516]。

+Presbyopia Correcting Intraocular Lens

+老花眼矫正人工晶状体

∞CATQUEST 9SF, patients were asked: Do you have difficulty with the activities because of your sight? If so, to what extent?

∞CATQUEST 9SF，患者被问到：由于你的视力，你的活动有困难吗？如果是这样，在多大程度上？

‡Subject satisfaction was evaluated with the Catquest 9SF Questionnaire. Statistic refers to ‘very’ or ‘fairly’ satisfied.

‡使用Catquest 9SF问卷评估受试者满意度。统计指的是“非常”或“相当”满意。

†Visual disturbances were evaluated by asking open, non-prompted questions about visual experience.

†通过询问关于视觉体验的开放式，非提示性问题来评估视觉障碍。

§IOLSAT: In the past 7 days, how often did you need to wear eyeglasses to see?

§IOLSAT：在过去的7天里，你需要多久戴一次眼镜才能看到？

*The Alcon Eye on Cataract survey was conducted between March and April 2023 in Australia, Brazil, China, Germany, India, Italy, Japan, Spain, South Korea and the United States, and set out to evaluate vision and cataract insights among the world’s rapidly aging population. Survey participants totaled 7,331, including 1,826 pre- and post-cataract surgery patients aged 50+ who had received their diagnosis within the last five years (both monofocal and multifocal intraocular lens recipients), and 5,505 people aged 50+ who had not been diagnosed with cataract(s) and who had not undergone surgery..

*爱尔康白内障调查于2023年3月至4月在澳大利亚，巴西，中国，德国，印度，意大利，日本，西班牙，韩国和美国进行，并着手评估世界视力和白内障的见解。人口迅速老龄化。调查参与者共7331人，其中包括1826名50岁以上的白内障手术前后患者，他们在过去五年内接受了诊断（单焦点和多焦点人工晶状体接受者），以及5505名50岁以上未被诊断患有白内障的人（s）和谁没有接受手术。。

Connect with us on

与我们联系

Facebook

脸谱网

LinkedIn

LinkedIn

X

X